UOC
CAPR icon

UBS O'Connor’s Capricor Therapeutics CAPR Stock Holding History

UBS O'Connor’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-17,054
Closed -$169K – 311
2025
Q2 		$169K Buy
+17,054
New +$180K ﹤0.01% 296
2025
Q1 		– Sell
-104,798
Closed -$1.45M – 357
2024
Q4 		$1.45M Buy
104,798
+21,898
+26% +$384K 0.04% 197
2024
Q3 		$1.26M Buy
+82,900
New +$410K 0.03% 251

Other funds holding CAPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PC
Pier Capital Stamford, Connecticut $606M AUM 63.41% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS O'Connor's CAPR Position: Q3 2025 in Review

UBS O'Connor sold out of Capricor Therapeutics (CAPR) in Q3 2025, closing a stake of 17,054 shares — an estimated $169K sold.

UBS O'Connor first reported a position in CAPR in Q3 2024 and held it in 3 quarters. The position peaked at $1.45M in Q4 2024. 115 funds tracked by Wall St. Rank hold CAPR as of Q3 2025.

  • UBS O'Connor reported no remaining Capricor Therapeutics position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 17,054 Capricor Therapeutics shares in Q3 2025, an estimated $169K.
  • UBS O'Connor first reported a position in Capricor Therapeutics in Q3 2024 and held it in 3 quarters.
  • UBS O'Connor's Capricor Therapeutics position peaked at $1.45M in Q4 2024.
  • 115 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.